Evogene loss widens to USD 7.66 million for six months; revenue drops 76% to USD 681,000
EVGN•Evogene reported a USD 7.66 million loss for the six months ended June 30, 2026, while revenue fell 76% year over year to USD 681,000.
1. Six-month results
Operating loss widened 11% to USD 5.39 million, and loss before income taxes widened 75% to USD 7.17 million. Net financing results swung to a loss of USD 1.74 million. Cash and cash equivalents fell to USD 9.32 million at June 30, 2026, from USD 12.96 million at December 31, 2025.
